Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Defibrillators”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,459 records · Page 81Linked to original sources
PubMed2004

[Public access defibrillators--beneficial?].

BACKGROUND: In Norway, every year more than 3000 persons suffer sudden cardiac death caused by ventricular fibrillation. The present recommendations of international expert committees are that the use of public-access defibrillators should be encouraged, including training of non-medical personnel. MATERIAL AND METHOD: In order to evaluate the validity of such recommendations, we performed searches in Medline on relevant keywords and evaluated articles thus identified and their references. We selected studies on countries, cities, public access defibrillator projects, and on epidemiology of cardiac arrest and ventricular fibrillation. RESULTS: Studies of the public-access defibrillation strategy reported the highest frequencies of survival. Studies from cities gave highly variable results; those for entire countries poor results. Different populations have different results of survival, and commonly used predictor models do not comprehensibly explain these findings. Over time there is a falling frequency of ventricular fibrillation as the cause of cardiac arrest. INTERPRETATION: Application of the strategy of public-access defibrillators will not result in significantly improved survival from cardiac arrest in Norway.

Cardiopulmonary Resuscitation↗
PubMed2006

Evaluation of the defibrillation threshold in atrial fibrillation by transoesophageal cardioversion using a biphasic impulse.

INTRODUCTION: Recurrent atrial fibrillation (AF) in the setting of haemodynamic disturbances requires frequently repeated cardioversions, which is associated with the risk of myocardial damage. It is thus necessary to identify methods which can minimise the cardioverter impulse energy. AIM: To define the defibrillation threshold in recent-onset AF using a biphasic impulse, following an infusion of magnesium, potassium, and amiodarone. METHODS: Transoesophageal cardioversion was performed in 32 patients with AF lasting < or =48 hours, in whom prior administration of 40 mEq K+, 4.0 g MgSO4 and 300 mg amiodarone did not restore sinus rhythm. Cardioversion was performed under short intravenous anaesthesia using a biphasic impulse travelling from a multi-annular oesophageal electrode to two electrodes on the anterior chest wall. The initial energy was set to 1 J, which was subsequently increased according to the following protocol: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 and 70 J. RESULTS: Electrical cardioversion following the administration of electrolytes and amiodarone restored sinus rhythm in all the patients (100% efficacy). The mean defibrillation threshold was 12.9+/-14.3 J, with a minimal effective energy of 1 J and a maximum effective energy of 70 J. The defibrillation threshold was in the range from 1 to 10 J in 75% of the patients. The mean cumulative energy transferred between electrodes during evaluation of the defibrillation threshold was 39.7 J (SD, 38.8). CONCLUSIONS: Transoesophageal cardioversion using a low-energy (mean, 12.9 J; range, 1-70 J) biphasic impulse, following the intravenous administration of potassium chloride and amiodarone, was 100% effective in restoring sinus rhythm in AF.

Adult↗
PubMed2006

Quality of life in patients with implantable cardioverter defibrillators.

BACKGROUND: The implantable cardioverter defibrillator (ICD) is a life saving device for individuals with life threatening ventricular arrhythmias. There is no doubt that it is a cost effective therapy in various congenital and acquired arrhythmogenic disorders. Nevertheless, shock delivery may be painful and frightening which causes psychological distress and deterioration of perceived quality of life. METHODS: A systematic meta-analysis on studies reporting quality of life in patients implanted with ICDs was done using professional databases. Related articles and references of the relevant articles were also searched for suitable studies. RESULTS: Thirty studies with a total of 3412 patients on implantable defibrillators were identified. Five of them were large randomised studies with a total of 1680 patients, while 25 were non-randomised studies. Medical Outcome Study 36-item Short Form health survey (SF -94 36) was the most common instrument used for assessment of quality of life. Only one of the 5 major randomised trial reported worsening of quality of life after implantation of a defibrillator. In the subgroup of patients receiving shocks, three out of the five trials reported worsening of quality of life. SUMMARY: Most of the randomised studies showed either neutral or better quality of life in patients on implantable defibrillators. In the subset of patients receiving shocks, worsening of quality of life was found in most randomised studies. Therefore, activation of antitachycardia pacing should be performed in every ICD-patient in order to miminze painful shocks and consequent deterioration of quality of life.

Journal Article↗
PubMed1991

[Combined anti-bradycardia/anti-tachycardia pacemaker-cardioverter-defibrillator systems in patients with recurrent ventricular tachyarrhythmias].

In 41 patients with recurrent sustained ventricular tachycardia and/or ventricular fibrillation an integrated pacemaker-defibrillator-system (PCD, Medtronic, model 7216 A or 7217 B) was implanted. In 21 out of 24 (88%) patients a new transvenous implantation technique in combination with a subcutaneous patch electrode was used. The implanted devices comprise antibradycardiac pacemaker functions, two different forms of antitachycardiac pacemaker functions (ramp and burst pacing), and internal cardioversion or defibrillation capabilities. During a mean follow-up of 8 months 147 episodes of ventricular tachycardia were detected, 131 of them were terminated successfully by antitachycardiac pacing; in 13 episodes internal cardioversion was applied to revert ventricular tachycardia. Twenty-seven episodes of ventricular fibrillation or rapid ventricular tachycardia (greater than 200/min) were detected and successfully terminated by internal defibrillation. In six patients with intermittent rapid atrial fibrillation, change of antiarrhythmic therapy was required to avoid activation of the device. The new integrated pacemaker-defibrillator systems improve therapy in patients with life-threatening tachyarrhythmias by reducing the number of internal cardioversions/defibrillations; the non-thoracotomy approach reduces the post operative risk.

Adult↗
PubMed1991

[Clinical experience with a second-generation cardioverter-defibrillator].

Implantable cardioverter defibrillators (ICD's) are effective for reducing mortality in refractory malignant ventricular arrhythmias (MVA). Second generation ICD's (Telectronics Guardian 4202/4203) were implanted in 7 patients (all male, mean age 58.1 years) with ventricular fibrillation (VF) in 2, ventricular tachycardia (VT) in 1, and both VF and VT in 4. Underlying heart disease was coronary artery disease in 4 patients, and valvular heart disease, dilated cardiomyopathy and no obvious cause (documented primary VF, reproducible at electrophysiologic study) in 1 patient each. Mean ejection fraction was 40 +/- 14%. Mean defibrillation threshold of the two epicardial patches at implantation by means of median sternotomy was 18 +/- 9 joule, and patch impedance 35 +/- 7 ohms. Post defibrillation bradypacing via epicardial electrode was programmed in 5 patients (70%). Mean follow-up was 10.1 months (1-25 months). Successful defibrillation of 28 spontaneous VT/VF episodes was noted in 2 patients, while the other 5 have had no further episodes of MVA so far. One device was explanted following tissue necrosis at the battery site after a MVA-recurrence-free interval of 15 months. The reconfirmation algorithm prevented false shock delivery in 2 patients.

Cardiac Pacing, Artificial↗
PubMed1990

Short-term morbidity and mortality of implantation of automatic implantable cardioverter-defibrillator.

Over the 3-year period from Jan. 1, 1986, through Dec. 31, 1988, we have implanted 101 automatic implantable cardioverter-defibrillators into patients with life-threatening ventricular arrhythmias. There were 82 male patients and 19 female patients. The mean age was 58 years with a range of 25 to 82 years. The indication for implantation was ventricular fibrillation in 89 patients and recurrent ventricular tachycardia in 12 patients. Seventy-seven patients had a history of prior myocardial infarction or coronary artery disease, or both. Eighteen patients had nonischemic cardiomyopathy. One patient had a prolonged QT syndrome and five patients had no evidence of preexisting structural heart disease. The mean injection fraction was 37% +/- 17%. Forty-one of the automatic implantable cardioverter-defibrillator implantations were associated with procedures necessitating cardiopulmonary bypass. The hospital mortality rate was 4% and the morbidity rate was 15%. The only statistical difference between those patients who did and did not have postoperative complications was a history of a prior myocardial infarction (90% versus 54%, p less than 0.05). Twenty percent of patients had new-onset postoperative atrial fibrillation after implantation of the device. Eleven percent of patients had sustained ventricular tachycardia postoperatively. Although there was a trend toward a higher complication/death rate in the patients whose automatic implantable cardioverter-defibrillator was inserted in association with cardiopulmonary bypass (24% versus 15%) and the occurrence of new-onset postoperative atrial fibrillation (27% versus 15%), these findings were not statistically significant. Automatic implantable cardioverter-defibrillator implantation with and without concomitant cardiopulmonary bypass is associated with a clinically important morbidity and mortality rate and development of postoperative arrhythmias.

Adult↗
PubMed1990

Catheter-type defibrillation electrode using glassy carbon: results of electrode implantation.

The implantable defibrillator, developed by Dr Michel Mirowski, is a remarkable electric therapeutic device which has been in clinical use since 1980 in the treatment of life-threatening arrhythmia. However, as the present life span of this device is only 3 years, research is being carried on to extend the lifetime with improved stimulation methods, circuits and electrodes. In particular, the electrode system which is inserted into the right ventricle has more than 50 times the electrode area of a pacing electrode and is prone to degradation. What is needed is biocompatibility and electrical stability, similar to that of cardiac pacemaker electrodes, which can be used for more than 10 years. For this purpose, we focused on a conductive ceramic as a new material for the defibrillation electrode instead of the previously-used metal. We selected glassy carbon as our electrode material and tested the surface condition through acute and chronic animal experiments. No clots formed around the electrodes after a 3-month implantation, nor were there surface disorders after the defibrillation stimulations. We concluded that glassy carbon is a promising material for future defibrillation electrodes.

Animals↗
PubMed1990

Initial clinical experience with the pacemaker-cardioverter-defibrillator.

The implantation of a new multiprogrammable pacemaker-cardioverter-defibrillator is reported in four patients suffering from drug-refractory ventricular tachycardia or fibrillation. The generator (PCD 7215; Medtronic Inc) was interfaced to the epicardium by three countershock patch electrodes and one ventricular myocardial screw-in lead for sensing/pacing. The device employs separate rate detection criteria for ventricular tachycardia and ventricular fibrillation with automatic delivery of up to four therapies per episode. Therapeutic options include: antitachycardia burst or autodecremental pacing, synchronized cardioversion, defibrillation and ventricular demand pacing at 30 to 90 beats/min. Four men and one woman (ages 29 to 75 years) underwent intraoperative implant evaluation, and the device was implanted in the four men. Over a follow-up of 1.5 to 23 months, 161 spontaneous episodes of ventricular tachycardia and nine episodes meeting ventricular fibrillation criteria (cycle length less than 280 to 290 ms) were detected and treated by the device. Ramp pacing was initially employed to terminate 140 ventricular tachycardia episodes and was successful 88.5% of the time while 10 (7.2%) required low energy epicardial cardioversion (4 to 10 J). Six (4.3%) episodes terminated spontaneously prior to therapy delivery. All nine spontaneous episodes of ventricular fibrillation were defibrillated using 10 to 15 J. Two patients continue to do well with the device functioning reliably. The device was removed at the time of heart transplant in one patient, while another patient died suddenly from drug overdose. No other complications, device malfunctions or inappropriate therapy delivery have been observed. These early results demonstrate the potential usefulness of a programmable device which provides graded therapy for ventricular tachycardia with added defibrillation and bradycardia pacing capability.

Adult↗
PubMed1987

[Automatic implantable cardioverter-defibrillator (AICD) and antitachycardia pacemaker (Tachylog 651) in the treatment of ventricular tachyarrhythmias].

For the electrotherapy of refractory ventricular tachycardia the automatic implantable cardioverter-defibrillator (AICD) and antitachycardia pacemaker are available. The long-term use of antitachycardia pacing is still limited by the potential risk of acceleration to ventricular fibrillation. To combine the advantages of antitachycardia pacing with back-up defibrillation, we evaluated the use of an antitachycardia pacemaker with the automatic defibrillator. The AICD was implanted in 13 patients with a mean age of 62 years (from 46 to 75 years); six of them with recurrent ventricular tachycardia (170 +/- 16 per minute) which could reliably be terminated by overdrive pacing, received also an antitachycardia pacemaker (Tachylog 651). The underlying cardiac disease was coronary heart disease in 11 patients and cardiomyopathy in 2 cases. All patients had survived 1 to 6 cardiac arrests and had not responded to 6 +/- 1.5 antiarrhythmic drugs. For antitachycardia pacing we used burst stimulation with 4 to 6 stimuli and coupling intervals from 260 to 300 ms. During the follow-up period of 12 +/- 2 months, 83% of 744 tachycardias could be terminated by burst stimulation, according to the diagnostic data of the pulse generator. If the pacemaker failed to terminate or in case of acceleration (three patients), the automatic countershock of the AICD (5-42 per patient) restored sinus rhythm. In seven patients with high rate tachycardia, 2 to 69 AICD discharges occurred. No patient died suddenly, but three died due to underlying disease and one because of a pneumonia postoperatively. Future antitachycardia devices should be flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.

Electric Countershock↗
PubMed1986

Special considerations for defibrillation performed by emergency medical technicians in small communities.

Defibrillation by minimally trained ambulance technicians can significantly improve survival after out-of-hospital cardiac arrest in communities of all sizes. However, special consideration must be given to the development of such services in small communities, chiefly because of problems associated with the low volume of true emergency calls. Communities considering implementing programs by which defibrillation is performed by the emergency medical technician (EMT-D) must first evaluate their ambulance response times and, if inadequate, alter their system of ambulance response. After implementation of such a program, a permanent, formal skill maintenance program must be established. Defibrillation protocols must allow for the fact that many patients will refibrillate after successful conversion, yet no advanced care beyond the defibrillator will generally be available. Finally, every community instituting an EMT-D program must maintain a system of monitoring EMT performance and patient outcome that documents acceptable survival-to-discharge rates as well as the safety of the program. For smaller communities a regional or statewide evaluation system may be preferable to individual community programs.

Allied Health Personnel↗
PubMed1986

Defibrillation performed by the emergency medical technician.

As a means of providing defibrillation as soon as possible for those suffering out-of-hospital ventricular fibrillation, numerous communities have trained and authorized emergency medical technicians (EMTs) to provide defibrillatory shocks (EMT-D). The findings of four controlled studies and the experience of various communities have answered important questions. EMT-D programs have been shown effective in urban, suburban, and rural communities with and without paramedic backup. EMT-D programs appear safe, with errors of commission being extremely rare and errors of omission being of acceptably low incidence. Issues still to be resolved include the degree and amount of training that should be given and whether manual or automatic defibrillators should be used. Medical supervision and quality control is the most important aspect of EMT-D programs. At its core, the success of EMT-D programs is confirmation of the principle of early defibrillation. Wider dissemination of early defibrillation will improve survival from sudden cardiac death.

Allied Health Personnel↗
PubMedDate not supplied

User views on standards for defibrillators.

User views on the need for defibrillator standards were surveyed as part of a multifaceted study of defibrillator use in Canadian hospitals. The majority of users favor standardization of performance, labeling, and use characteristics. They also prefer that all defibrillators incorporate cardioversion capability. Most users prefer that the defibrillator automatically switch to the emergency mode after delivery of a cardioversion shock, but almost one half of the physicians preferred the unit to remain in the synchronized mode as set. Most users are in favor of all equipment operating in the same fashion, but paramedics are not. Only a minority believes that cardioversion features are a cause of confusion, yet conversations with biomedical engineers indicate that this confusion is a common problem among the users. Virtually all users prefer that necessary standards for safety and efficacy should be mandatory for both manufacturers and hospitals.

Attitude of Health Personnel↗
PubMed1985

Clinical experience with the automatic implantable defibrillator.

Since February 1980, worldwide, over 400 survivors of sudden arrhythmic death have been treated with the automatic implantable defibrillator. Recently, the device has been further improved; it is now a cardioverter-defibrillator (AICD), able to treat ventricular tachycardias as well as ventricular fibrillation. There are two defibrillating electrodes which are used also for waveform analysis; one is located in the superior vena cava, the other is placed over the cardia apex. A third bipolar right ventricular electrode serves for rate counting and R-wave synchronization. When ventricular fibrillation occurs, a 25-joule pulse is delivered; when ventricular tachycardia faster than a preset rate is detected, the discharge is R-wave synchronized. Special batteries can deliver over 100 shocks or provide a three-year monitoring life. Implantation of the device can be achieved through a thoracotomy or by a subxiphoid or a subcostal approach. Thus far, the longest follow-up period has been 58 months. Actuarial analysis shows the one-year mortality attributed to arrhythmias reduced to less than 2%. Thus, the automatic cardioverter-defibrillator can reliably identify and correct potentially lethal ventricular tachyarrhythmias, leading to a substantial increase in survival in properly selected high-risk patients.

Death, Sudden↗
PubMedDate not supplied

Development of standard test methods for evaluating defibrillation recovery characteristics of disposable ECG electrodes.

A clinically relevant test for the measurement of defibrillation overload recovery of prefilled disposable ECG electrodes was developed and is proposed for use in an ECG electrode standard under development by AAMI. Defibrillation overload voltages and currents, as well as electrode polarization recovery voltages, were first measured in animal tests on 12 types of electrodes to allow correlation with various bench tests using a capacitor discharge at 10, 200, or 1000 V. Current overloads absorbed by the electrodes under worst conditions in animal tests were in the range of 2 percent of the defibrillation current flowing through the chest. These overloads were absorbed by most Ag-AgCl electrodes without excessive polarization. However, stainless steel, brass, and tin electrodes tended to polarize to levels that would saturate many ECG monitors. A standard bench test using a 200-V 10-muF capacitor was recommended for inclusion in the AAMI standard to determine whether electrodes are acceptable for use during defibrillation.

Animals↗
PubMed1978

[Optimal parameters for electrical auricular defibrillation].

In acute experiments on dogs the chest was opened and auricular flutter and fibrillation were induced. Current, energy and charge thresholds which eliminated this arrhythmia by the monopolar direct impulse of 1--15 ms duration were determined. The current and energy values that evoked the auricular defibrillation during direct application of the electrodes to them were minimal when the impulses of 8 ms were used: 113 +/- 13.7 mA and 10.4 +/- 2.6 mWs in elimination of the flutter, and 275 +/- 18.2 mA and 62.3 +/- +/- 9.0 mWsec in elimination of the fibrillation. The current that restored the nomotopic rhythm during direct auricular defibrillation was 50 times less than that determined during the transthoracic auricular defibrillation in dogs. The efficacy of direct auricular defibrillation indicated the necessity of the elaboration of an adequate method for its application in clinical practice.

Animals↗
PubMed1978

Effect of shock strength on survival and acute cardiac damage induced by open-thorax defibrillation of dogs.

The safety of open thorax defibrillation with single damped sine-wave shocks and 6-cm-diameter electrodes was evaluated in healthy anesthetized dogs. Twenty-one dogs were allotted to 6 groups: Group A were nonshocked controls and groups B through F were given single shocks of 4-, 7-, 12-, 19-, or 32-fold, respectively, greater than a defibrillation threshold dose (30 mA/g of heart). Immediate postshock death resulted in group F dogs; group A through E dogs survived and were killed after 2 days. The incidence and severity of cardiac morphologic damage increased with shock strength (mild damage occurred in 1 of 3 dogs in group C and in 3 of 4 dogs in group D and severe damage occurred in 2 of 3 dogs in group E). The cardiac lesions were characterized grossly and microscopically. In dogs that died immediately after shocking, damage was apparent as pale circular zones of edema and myofibrillar degeneration in the ventricular free walls beneath the electrode placement sites on the cardiac surface. In the dogs that survived 2 days, the defibrillator-induced areas of myocardial necrosis and calcification were concentrated in arc or ringlike patterns beneath the periphery of the electrode placement sites. All dogs that were studied 2 days after shocking had mild fibrinous pericarditis. Postshock electrocardiographic changes were not good indicators of cardiac damage because the mild epicardial inflammatory reaction associated with the surgical procedure produced large ST and T wave changes which masked any changes associated with myocardial necrosis induced by the electric shocks. It was concluded that a substantial safety margin exists between the required defibrillation threshold shock dose and the large shocks required to produce marked cardiac damage or death in healthy dogs.

Animals↗
PubMed1984

Use of the automatic implantable cardioverter-defibrillator in the treatment of malignant ventricular tachyarrhythmias.

Since February, 1980 nearly 200 automatic cardioverter - defibrillators have been implanted in patients with malignant ventricular arrhythmias. The currently-employed device weighs 298 grams and occupies a volume of 162 cm3. There are two defibrillation electrodes which also serve as sensors: one, an intravascular catheter placed in the superior vena cava at the level of the right atrium; the other, a flexible rectangular patch placed extrapericardially over the apex of the heart. Additionally, there is a bipolar right ventricular electrode for rate counting and R-wave synchronization which will eventually be used for pacing as well. The unit is powered by lithium batteries with a projected monitoring life of three years, or the capability of discharging approximately 100 times. The arrhythmia detector activates the cardioverter -defibrillator about 15 to 20 seconds after diagnosing a "treatable" arrhythmia, identified on the basis of a striking absence of isoelectric potential segments characteristic of ventricular fibrillation and many ventricular tachycardias. The diagnosis also requires fulfillment of individually-programmed heart rate criteria. If the initial discharge of 25 joules is ineffective, the device will recycle as many as three times with a final pulse of up to 42 joules. Of the twelve nonsurvivors among the initial 52 implantees who underwent implantation through September, 1982, only four deaths were unwitnessed and considered to be sudden and arrhythmic; the other eight deaths were due to heart failure or unrelated causes. Thus, from a predicted mortality of 48% in the same group of patients if the automatic defibrillator had not been implanted, the "sudden death" mortality was reduced to 8.5%.

Electrocardiography↗
PubMed1983

Trials of the automatic implantable defibrillator in man. A three-year program report.

Since February, 1980, 65 survivors of multiple arrhythmic cardiac arrests unresponsive to therapy were referred for implantation of the automatic defibrillator. In 37 patients (Group I), automatic defibrillator implantation alone was performed by subxiphoid insertion (20 patients) or thoracotomy (17 patients). In another 28 patients (Group II), implantation was combined with definitive cardiac procedures--coronary artery bypass grafting in seven patients, bypass grafting and mitral valve replacement in four patients, and left ventricular aneurysmectomy with endocardial resection in 17 patients. There were no surgical deaths in Group I; four operative deaths occurred in Group II. The longest follow-up has been 34 months, average 15.6 months. Following hospital discharge, 44 episodes of automatic out-of-hospital resuscitation were observed in 11 Group I patients. Similarly, four resuscitations were observed in two Group II patients. Hypothetical survival curves based on the assumption that these out-of-hospital resuscitations were lifesaving indicated expected 1 year survivals rates of 45% in Group I and 85% in Group II. Excluding the perioperative deaths that were unrelated to the defibrillator, the actual 1 year survival rates observed were 75% and 95% in Groups I and II, respectively. Although definitive operation markedly reduced the number of out-of-hospital arrhythmic episodes, the automatic defibrillator appears to increase survival both when implanted alone and when used in combination with cardiac procedures.

Adolescent↗